SARMNon-steroidalSARMExperimental

BMS-564929

Also known as BMS564929 · BMS-564929

Written by enwyReviewed 15 Jul 20261 sources0 comments

BMS-564929 is an experimental non-steroidal SARM from Bristol-Myers Squibb noted in preclinical work for very high anabolic potency and strong tissue selectivity for muscle over prostate. It is highly suppressive of the HPG axis in animal models and has no established human efficacy or safety data.

01 Overview

BMS-564929 was characterised as a potent, orally active SARM with a large separation between muscle-anabolic and prostate-androgenic effects in castrated rat models. Its high potency meant active doses were low, and it markedly suppressed luteinising hormone and endogenous testosterone in animals.

BMS-564929 did not reach published human efficacy trials and is not approved. Grey-market presence is limited. Because of its potency and strong suppression in animals, extrapolated human dosing is especially uncertain, and all data remain preclinical.

02 Mechanism

Potent non-steroidal androgen receptor agonist with strong selectivity for anabolic effects in skeletal muscle over androgenic effects in the prostate in preclinical models.

03 Dosing

Tier	Dose	Route	Notes
Anecdotal	1–5 mg/day	Oral	High potency; no human data, speculative low-milligram range.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Increased muscle massPotent anabolic effect on skeletal muscle in castrated rat models.		Preclinical
High tissue selectivityLarge muscle-versus-prostate selectivity margin in animals.		Preclinical

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Uncharacterised human toxicityNo human safety data; potency raises concern about narrow margins.	Moderate	Uncharacterised	Unconfirmed
Strong HPTA suppressionPronounced suppression of LH and endogenous testosterone in animal models.	Severe	Marked in animals	Preclinical

06 Legal status

United States

Not approved; experimental

Not FDA-approved; banned in sport by WADA. · as of Jan 2026

07 References

Discovery and characterization of BMS-564929, a novel muscle-selective androgen receptor modulatorJournal of Medicinal Chemistry / Endocrinology, 2007

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.